Physica System KR Vs Physica System CR (K-20)

NCT ID: NCT04594447

Last Updated: 2025-03-10

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 3 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-09-30
• Study Completion Date: 2024-04-01

Brief Summary

Post-market, monocentric, randomised, open-label, parallel group, prospective study conducted in patients who have to perform a total knee replacement (TKR) with Physica KR or Physica CR system.

Detailed Description

The aim of the study is to evaluate the clinical, radiographic and PROMs outcomes of Total Knee Arthroplasty (TKA) with 2 Lima TKR design: Physica KR and Physica CR (randomization 1:1) from preoperative to 1-year follow-up.

Conditions

Total Knee Replacement

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Physica KR

Subject that receive Physica Kinematic Retaining total Knee replacement system

Group Type: OTHER

Physica Kinematic Retaining knee replacement

Intervention Type: DEVICE

modular knee prosthesis with a Kinematic Retaining (KR) mechanism and posterior cruciate ligament (PCL) preservation

Physica CR

Subject that receive Physica Cruciate Retaining total Knee replacement system

Group Type: OTHER

Physica Cruciate Retaining knee replacement

Intervention Type: DEVICE

modular knee prosthesis with posterior cruciate ligament (PCL) preservation

Interventions

Physica Kinematic Retaining knee replacement

modular knee prosthesis with a Kinematic Retaining (KR) mechanism and posterior cruciate ligament (PCL) preservation

Intervention Type: DEVICE

Physica Cruciate Retaining knee replacement

modular knee prosthesis with posterior cruciate ligament (PCL) preservation

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Males and females of any race requiring a total knee replacement and suitable for the use of one of the two configurations of the Physica system.

2. Age ≥ 18 years old,

3. Patients who are suffering from non-inflammatory degenerative joint disease (NIDJD): including knee osteoarthritis, post-traumatic knee arthritis, avascular necrosis; or patient who are suffering from inflammatory joint disease including rheumatoid arthritis.

4. Suitable candidates for TKR who have undamaged and functional collateral ligaments

5. Suitable candidates for TKR with Physica KR and CR who have an undamaged and functional posterior cruciate ligament.

6. Patients who understand the conditions of the study and are willing and able to comply with the prescribed rehabilitation and to perform all scheduled follow-up visits.

7. Patients who have signed the Ethics Committee/IRB approved study-specific Informed Consent Form prior to the surgery.

Exclusion Criteria

1. Patients with severe instability of the knee joint secondary to the absence of collateral ligament integrity and/or function.

2. Patients with active or any suspected infection (on the affected knee or systemic)

3. Previous partial knee replacement (unicompartmental, bicompartmental or patellofemoral joint replacement), patellectomy, high tibial osteotomy

4. Patients with significant bone loss on femoral or tibial joint side

5. Current treatment for malignant and/or life-threatening nonmalignant disorders

6. Patients with known incompatibility or allergy to the product materials, and/or metal hypersensitivity to implant materials

7. Patient with open epiphyses (immature patient with active bone growth).

8. Vascular insufficiency of lower limbs severe enough to interfere with the study evaluation

9. Patients with bone stock compromised by disease, infection or prior implantation that cannot provide adequate support and/or fixation to the prosthesis

10. Patients with systemic or metabolic disorders leading to progressive bone deterioration which may impair fixation and stability of the implant

11. Any concomitant disease and dependence that might affect the performance of the implanted prosthesis

12. Any clinically significant pathology based on clinical history that the Investigator feels may affect the study evaluation (e.g. primary osteoporosis with significant bone loss, haemophilic disease, septicaemia, persistent acute or chronic osteomyelitis)

13. Patients who have significant neurological or musculoskeletal disorders or disease that may adversely affect gait and compromise functional recovery and evaluation

14. Patients who have neuromuscular or neurosensory deficit which would limit the ability to assess the performance of the device

15. Previous history of infection in the affected joint and/or other local/systemic infection that may affect the prosthetic joint

16. Any psychiatric illness that would prevent comprehension of the details and nature of the study

17. Patients currently participating in any other surgical intervention studies or pain management studies

18. Female patients who are pregnant, nursing, or planning a pregnancy.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

NAMSA

OTHER

Sponsor Role: collaborator

Limacorporate S.p.a

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

The Royal Bournemouth Hospital

Bournemouth, Dorset, United Kingdom

Countries

United Kingdom

Other Identifiers

K-20

Identifier Type: -

Identifier Source: org_study_id